This chapter discusses the safety and regulation of peptides, emphasizing the strict protocols followed by FDA regulated compounding pharmacies. They highlight the need for accurate information and more conversations with the FDA to represent small compounding pharmacies. They also criticize the FDA for limiting access to certain drugs and express concerns about the lack of oversight on big pharma manufacturing facilities.